[Claims]

[Claim 1]
A composition for use in treating dry eye, comprising (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, wherein the composition is a suspension.

[Claim 2]
The composition of claim 1, wherein (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide.

[Claim 3]
The composition of claim 1 or 2, wherein the dry eye is accompanied by a subjective symptom.

[Claim 4]
The composition of claim 3, wherein the dry eye is accompanied by ocular discomfort associated with dryness.

[Claim 5]
The composition of claim 1 or 2, wherein the dry eye is accompanied by an objective symptom.

[Claim 6]
The composition of claim 1 or 2, wherein the dry eye is accompanied by a subjective symptom and an objective symptom.

[Claim 7]
The composition of any one of claims 1 to 6, wherein a concentration of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof is 0.1 to 1.0 w/v %.

[Claim 8]
The composition of any one of claims 1 to 7, which is an eye drop.

[Claim 9]
The composition of any one of claims 1 to 8, wherein the dry eye is aqueous deficient dry eye.

[Claim 10]
The composition of any one of claims 1 to 9, characterized in that the composition is administered to a patient who has a subjective symptom of ocular discomfort and has been diagnosed as having dry eye.

[Claim 11]
A suspension for use in suppressing ocular discomfort associated with dryness, comprising 0.3 to 1.0 w/v % of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof.

[Claim 12]
The suspension of claim 11, wherein (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide.